Presentation Date:
Time:
Webcast: Atossa Therapeutics Presentation Link
ABOUT
FORWARD-LOOKING STATEMENTS DISCLAIMER STATEMENT
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence and continue studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study or reduction of breast density will be approvable endpoints for oral Endoxifen, and other risks detailed from time to time in Atossa's filings with the
Contact:
CFO and General Counsel
Office: (866) 893-4927
E: KYLE.GUSE@ATOSSAINC.COM
INVESTOR
Office: (516) 222-2560
E: IR@ATOSSAINC.COM
(C) 2022 Electronic News Publishing, source